#CanSino Biologics today announced that its #Shanghai subsidiary has received 1.1 billion yuan in backing to gear up for production of the company’s recombinant Covid-19 vaccine. SPH CanSino will become the producer of the company’s Covid-19 vaccine that has been approved by Chinese regulators for use in certain specific conditions. The vaccine has also been cleared for emergency use in Mexico, Pakistan, Hungary and Chile. The facility is expected to start trial production in June and to be fully up and running by the end of the year, when it will have an annual output of 200 million doses.
